Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients.

about

Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.

P2860

Q37707098-02238094-F870-4E7C-B7DB-6DB6DF73A7BD

P2860

Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients.

Item

http://www.wikidata.org/entity/Q36140902

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Platelet response during the s ...... odysplastic syndrome patients.

@ast

Platelet response during the s ...... odysplastic syndrome patients.

@en

type

Item

label

Platelet response during the s ...... odysplastic syndrome patients.

@ast

Platelet response during the s ...... odysplastic syndrome patients.

@en

prefLabel

Platelet response during the s ...... odysplastic syndrome patients.

@ast

Platelet response during the s ...... odysplastic syndrome patients.

@en

P1476

Platelet response during the s ...... odysplastic syndrome patients.

@en

P2093

Chi Hoon Maeng

http://www.w3.org/2001/XMLSchema#string

Chul Won Jung

http://www.w3.org/2001/XMLSchema#string

Hyun Ae Jung

http://www.w3.org/2001/XMLSchema#string

Jun Ho Jang

http://www.w3.org/2001/XMLSchema#string

Moonjin Kim

http://www.w3.org/2001/XMLSchema#string

Sungmin Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

The effect of decitabine on megakaryocyte maturation and platelet release.

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.

P304

16653-16662

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.3914

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275835241

http://www.w3.org/2001/XMLSchema#string

P698

25938546

http://www.w3.org/2001/XMLSchema#string

P932

4599296

http://www.w3.org/2001/XMLSchema#string

Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients.

about

P2860

P2860

Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932